 There is something uniquely exciting about being the first company to bring a much-needed product to market. Outlook Therapeutics Inc NASDAQ:OTLK is hoping to become the first and only company to commercialize a US Food Drug Administration FDA approved ophthalmic formulation of bevacizumab, otherwise known as the cancer drug Avastin, for use in a damaging retinal condition known as wet age-related macular degeneration, or wet AMD. 